Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorDavid R. Kilpatrick
Estimating the term…
The ability to rapidly detect wild polioviruses in clinical specimens is a major concern for the world-wide eradication of polioviruses. Provided is a method of detecting polioviruses of all three serotypes from viral isolates of clinical specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 poliovaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested positive. All 14 prototype strains of nonpoliovirus enteroviruses tested negative. Also provided is a series of degenerate PCR primers that differentiates between the three wild poliovirus serotypes and a method of detecting the presence of the three serotypes utilizing a nucleic acid amplification technique.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:23 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:22 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:25 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:24 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:27 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:26 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:28 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:23 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:22 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:25 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:24 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:27 and which is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:26 and which primes poliovirus specific amplification or is a poliovirus specific probe.
An isolated nucleic acid of from 10-100 nucleotides that selectively hybridizes with and has at least 80% complementarity with a nucleic acid that is fully complementary to a nucleic acid having the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:28 and which is a poliovirus specific probe.
Dependencies are inferred from the claim text.